Altogether, we believe that targeting TNFR2 using its proper antagonist is an effective way for cancer treatment, since not only it efficiently controls immunosuppression by EPCs and other TNFR2+ immunosuppressive cells but also tumor angiogenesis and survival. This evidence concerns the gene TNFRSF1B and cancer.